Keith Fuleki
Family Medicine · Albion, NYNPI 1801233135
Payments from drug & device makers
Across 135 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$336
- Lilly USA, LLC$321
- AbbVie$233
- Gilead$212
- Novo Nordisk$197
- Johnson & Johnson$179
- plus $877 from 17 others
What the payments were for
- Food & beverage$2,349100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 21 | $336 |
| Lilly USA, LLC | 19 | $321 |
| AbbVie(2 entities) | 13 | $233 |
| Gilead | 10 | $212 |
| Novo Nordisk | 13 | $197 |
| Johnson & Johnson | 10 | $179 |
| AstraZeneca | 10 | $155 |
| Pfizer | 7 | $137 |
| Amgen | 6 | $105 |
| Amarin Pharma, Inc. | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Novartis | 3 | $58 |
| Boehringer Ingelheim | 2 | $54 |
| Merck | 3 | $53 |
| Edwards Lifesciences | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Indivior Inc. | 1 | $13 |
How this compares
$2,355 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $43,805 |
| EliquisApixaban | 24 | $26,845 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $18,770 |
| JardianceEmpagliflozin | 16 | $14,355 |
| FarxigaDapagliflozin Propanediol | 12 | $14,060 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,761 |
| Atrovent HfaIpratropium Bromide | 16 | $8,034 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,120 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,673 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,432 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $2,893 |
| Icosapent Ethyl | 12 | $2,630 |
| Omeprazole | 74 | $1,201 |
| Gabapentin | 114 | $1,165 |
| Celecoxib | 40 | $1,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $197 | $43,80535 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $336 | $38,65164 claims |
| PfizerEliquis | $137 | $26,84524 claims |
| AstraZenecaFarxiga, Symbicort | $155 | $19,73332 claims |
| Boehringer IngelheimJardiance | $54 | $14,35516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.
Other family medicine in Albion
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.